Nuvation Bio Statistics
Total Valuation
Nuvation Bio has a market cap or net worth of $1.95 billion. The enterprise value is $1.46 billion.
Important Dates
The next estimated earnings date is Thursday, March 5, 2026, after market close.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nuvation Bio has 342.83 million shares outstanding. The number of shares has increased by 42.08% in one year.
| Current Share Class | 341.83M |
| Shares Outstanding | 342.83M |
| Shares Change (YoY) | +42.08% |
| Shares Change (QoQ) | +0.48% |
| Owned by Insiders (%) | 24.88% |
| Owned by Institutions (%) | 57.31% |
| Float | 231.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 72.41 |
| Forward PS | 12.82 |
| PB Ratio | 6.00 |
| P/TBV Ratio | 6.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 54.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.48, with a Debt / Equity ratio of 0.18.
| Current Ratio | 8.48 |
| Quick Ratio | 8.26 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -32.82 |
Financial Efficiency
Return on equity (ROE) is -52.49% and return on invested capital (ROIC) is -32.45%.
| Return on Equity (ROE) | -52.49% |
| Return on Assets (ROA) | -24.82% |
| Return on Invested Capital (ROIC) | -32.45% |
| Return on Capital Employed (ROCE) | -43.67% |
| Weighted Average Cost of Capital (WACC) | 12.56% |
| Revenue Per Employee | $91,918 |
| Profits Per Employee | -$747,354 |
| Employee Count | 291 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +132.65% in the last 52 weeks. The beta is 1.53, so Nuvation Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.53 |
| 52-Week Price Change | +132.65% |
| 50-Day Moving Average | 7.52 |
| 200-Day Moving Average | 4.17 |
| Relative Strength Index (RSI) | 38.44 |
| Average Volume (20 Days) | 6,594,795 |
Short Selling Information
The latest short interest is 47.95 million, so 13.99% of the outstanding shares have been sold short.
| Short Interest | 47.95M |
| Short Previous Month | 45.98M |
| Short % of Shares Out | 13.99% |
| Short % of Float | 20.71% |
| Short Ratio (days to cover) | 7.78 |
Income Statement
In the last 12 months, Nuvation Bio had revenue of $26.75 million and -$217.48 million in losses. Loss per share was -$0.64.
| Revenue | 26.75M |
| Gross Profit | 14.51M |
| Operating Income | -232.97M |
| Pretax Income | -217.48M |
| Net Income | -217.48M |
| EBITDA | -231.55M |
| EBIT | -232.97M |
| Loss Per Share | -$0.64 |
Full Income StatementBalance Sheet
The company has $549.05 million in cash and $57.55 million in debt, with a net cash position of $491.50 million or $1.43 per share.
| Cash & Cash Equivalents | 549.05M |
| Total Debt | 57.55M |
| Net Cash | 491.50M |
| Net Cash Per Share | $1.43 |
| Equity (Book Value) | 325.88M |
| Book Value Per Share | 0.95 |
| Working Capital | 509.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$190.00 million and capital expenditures -$252,000, giving a free cash flow of -$190.25 million.
| Operating Cash Flow | -190.00M |
| Capital Expenditures | -252,000 |
| Free Cash Flow | -190.25M |
| FCF Per Share | -$0.55 |
Full Cash Flow StatementMargins
| Gross Margin | 54.26% |
| Operating Margin | -870.98% |
| Pretax Margin | -813.07% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nuvation Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -42.08% |
| Shareholder Yield | -42.08% |
| Earnings Yield | -11.13% |
| FCF Yield | -9.74% |
Analyst Forecast
The average price target for Nuvation Bio is $10.89, which is 91.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.89 |
| Price Target Difference | 91.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 113.86% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nuvation Bio has an Altman Z-Score of -0.94 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.94 |
| Piotroski F-Score | 3 |
